Review



aquabluer multitarget pharmaceuticals  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    TargetMol aquabluer multitarget pharmaceuticals
    Aquabluer Multitarget Pharmaceuticals, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/Multi-Target+Compound+Library/pm41349546-971-147-160
    Average 94 stars, based on 33 article reviews
    aquabluer multitarget pharmaceuticals - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Erianin facilitates pyroptosis in endometrial cancer via targeting m6A reader YTHDF1.
    Article Snippet: A compound library containing 60 natural compounds and erianin was obtained from TargetMol (Boston, MA, USA).

    Article Title: Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation
    Article Snippet: A compound library containing 996 bioactive compounds was provided by TargetMol.

    Article Title: Pan-cancer analysis of NTRK2 (TRKB) and the anticancer effect of its inhibitor Lucitanib in glioma.
    Article Snippet: Neurotrophic tyrosine receptor kinase 2 (NTRK2/TRKB) demonstrates oncogenic roles across cancers, with notable significance in gliomas where its overexpression is linked to aggressive clinical phenotypes.. Lucitanib (AL3810), a multi-target tyrosine kinase inhibitor, shows unexplored potential for treating NTRK2-driven gliomas.. This study employed an integrated approach combining pan-cancer analysis, computational drug screening, and experimental validation to systematically evaluate the oncogenic function of NTRK2 and the therapeutic efficacy of Lucitanib.

    Article Title: The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases
    Article Snippet: The senotherapeutic agents screened in this study were commercially acquired from TargetMol L8200-Anti-ageing Compound Library.

    Article Title: The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases.
    Article Snippet: The senotherapeutic agents screened in this study were commercially acquired from TargetMol L8200-Anti-aging Compound Library.

    Article Title: Erianin facilitates pyroptosis in endometrial cancer via targeting m6A reader YTHDF1
    Article Snippet: A compound library containing 60 natural compounds and erianin was obtained from TargetMol (Boston, MA, USA).

    Drug discovery:

    Article Title: OmniBind: Proteome-Wide Promiscuity Predictions for Early-Stage Drug Screening
    Article Snippet: .. The TargetMol compound library is available at https://www.targetmol.com/ . ..




    Similar Products

    aquabluer multitarget pharmaceuticals  (TargetMol)
    94
    TargetMol aquabluer multitarget pharmaceuticals
    Aquabluer Multitarget Pharmaceuticals, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/Multi-Target+Compound+Library/pm41349546-971-147-160
    Average 94 stars, based on 1 article reviews
    aquabluer multitarget pharmaceuticals - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    mt-htb (multitarget hcc blood test)  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals mt-htb (multitarget hcc blood test)
    Mt Htb (Multitarget Hcc Blood Test), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/hcc+blood+test/pm40308043-4-38-39
    Average 90 stars, based on 1 article reviews
    mt-htb (multitarget hcc blood test) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget immunoassay  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget immunoassay
    Multitarget Immunoassay, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+immunoassay/pmc09631676__advancesADV2022007493___suppl1-240-0-0
    Average 90 stars, based on 1 article reviews
    multitarget immunoassay - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    next-generation multitarget fecal dna test  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals next-generation multitarget fecal dna test
    Next Generation Multitarget Fecal Dna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+stool+test/pm40610389-148-7-8
    Average 90 stars, based on 1 article reviews
    next-generation multitarget fecal dna test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    small-molecule and a multitarget tki anlotinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals small-molecule and a multitarget tki anlotinib
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/anlotinib/pmc12198539-51-6-4
    Average 90 stars, based on 1 article reviews
    small-molecule and a multitarget tki anlotinib - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget car-t cells  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget car-t cells
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Multitarget Car T Cells, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+car+t+cells/pm40545042-291-0-0
    Average 90 stars, based on 1 article reviews
    multitarget car-t cells - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget therapeutic strategies  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget therapeutic strategies
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Multitarget Therapeutic Strategies, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+therapeutic+strategy/pm40536110-18-7-7
    Average 90 stars, based on 1 article reviews
    multitarget therapeutic strategies - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget dbs  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget dbs
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Multitarget Dbs, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+dbs/pm40526321-347-10-10
    Average 90 stars, based on 1 article reviews
    multitarget dbs - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget anticancer agents  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget anticancer agents
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Multitarget Anticancer Agents, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/anticancer+copper+ii++multitarget+pro+drug/pm40515697-626-20-20
    Average 90 stars, based on 1 article reviews
    multitarget anticancer agents - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multitarget therapeutic strategy  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget therapeutic strategy
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Multitarget Therapeutic Strategy, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget/multitarget+therapeutic+strategy/pm40518022-307-17-17
    Average 90 stars, based on 1 article reviews
    multitarget therapeutic strategy - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques:

    HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques:

    Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques: